September 23, 2019 07:14 AM EDTUpdated 07:32 AM
Financing

Amid Wood­ford de­ba­cle, Im­muno­core cuts val­u­a­tion as it se­cures $74M from Gen­er­al At­lantic — re­port

Amber Tong

Im­muno­core ap­pears to be the lat­est domi­no to fall around Neil Wood­ford’s de­ba­cle as it so­lic­its new back­ing at a dras­ti­cal­ly low­er val­u­a­tion.

Once a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times